Binnopharm Group expands its line of antiepileptic drugs
01.03.2024
Binnopharm Group launches production of Gabapentin, expanding the line of modern generics in the growing segment of antiepileptic drugs. The first batches of the drug in the form of 300 mg tablets will appear in pharmacies in March.
Gabapentin will be produced at the pharmaceutical company ALIUM, Binnopharm Group's own production facility in the Moscow region. The drug is indicated for use in adults and children from 12 years of age for the treatment of epilepsy and pain caused by nerve cell malfunction.
Binnopharm Group's portfolio already includes several antiepileptic drugs: Levetiracetam, Topiramate, Carbamazepine and Oxcarbazepine. By launching a new product on the market, the company is expanding its product line and expects to take a leading position in this sought-after segment.
The average annual growth of this market is 42 %, and the volume in value terms currently amounts to 4 billion rubles.
Sergey Komarov, Director of Planning and Business Analytics at Binnopharm Group: "We are constantly analyzing market needs and working on expanding our drug portfolio. During the year, with our R&D center operating at full capacity, we plan to increase the number of developments and improve the quality. Good market availability of high-quality, affordable drugs for popular nosologies, including our own, gradually reduces the dependence of the domestic pharmaceutical industry on foreign suppliers".
Gabapentin will be produced at the pharmaceutical company ALIUM, Binnopharm Group's own production facility in the Moscow region. The drug is indicated for use in adults and children from 12 years of age for the treatment of epilepsy and pain caused by nerve cell malfunction.
Binnopharm Group's portfolio already includes several antiepileptic drugs: Levetiracetam, Topiramate, Carbamazepine and Oxcarbazepine. By launching a new product on the market, the company is expanding its product line and expects to take a leading position in this sought-after segment.
The average annual growth of this market is 42 %, and the volume in value terms currently amounts to 4 billion rubles.
Sergey Komarov, Director of Planning and Business Analytics at Binnopharm Group: "We are constantly analyzing market needs and working on expanding our drug portfolio. During the year, with our R&D center operating at full capacity, we plan to increase the number of developments and improve the quality. Good market availability of high-quality, affordable drugs for popular nosologies, including our own, gradually reduces the dependence of the domestic pharmaceutical industry on foreign suppliers".
